A Practice Note discussing key antitrust issues relating to reverse payment settlement agreements, also known as pay-for-delay agreements. The Note focuses on patent infringement reverse payment settlements in the pharmaceutical industry involving brand-name and generic drug manufacturers, covers the US Supreme Court's decision in FTC v. Actavis and subsequent cases, and provides an overview of government and private enforcement activity.